# US 2023/0181659 A1 · Phage-mediated delivery of genes to gut microbiome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0181659 A1
- Document ID: US20230181659A1
- Status: Published application
- Kind: A1
- Application number: 17/923,865
- Filed: 2021-05-13
- Published: 2023-06-15
- Earliest claimed: 2020-05-14
- Assignees: CZ Biohub SF, LLC; The Regents of the University of California
- Applicants: Cz Biohub Sf, LLC; The Regents of the University of California
- Inventors: Kathy Lam; Peter Spanogiannopoulos; Peter Turnbaugh
- Web page: https://patentgrep.com/patent/US20230181659A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- C12N 1/20: Bacteria; Culture media therefor
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2795/14132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/14143: viral genome or elements thereof as genetic vector
- C12N 2795/14171: Demonstrated in vivo effect
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides materials and methods for selectively engineering at least one bacterial strain among a mixed population of bacterial strains in the gut of a subject. In some embodiments, a bacteriophage comprising at least one nucleic acid is administered which selectively infects a bacterial strain under conditions that allow expression of the nucleic acid. The present disclosure thus provides compositions and methods for precisely modifying or reducing a population of bacteria in a mixed population in the gut microbiome.

## Claims

### Claim 1

A method of selectively engineering at least one bacterial strain among a mixed population of bacterial strains in the gut of a subject comprising administering at least one bacteriophage comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain under conditions that allow expression of said at least one nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1 wherein the at least one bacterial strain is a member of a species selected from the group consisting of Escherichia coli, Escherichia albertii, Klebsiella pneumoniae, and Salmonella typhimurium.

### Claim 3 (depends on 1)

The method of claim 1 wherein the at least one bacterial strain is a member of a genus selected from the group consisting of Escherichia, Salmonella, Shigella, and Klebsiella

### Claim 4 (depends on 1)

The method of claim 1 wherein the at least one bacterial strain is a member of Enterobacteriaceae.

### Claim 5 (depends on 1)

The method of claim 1 wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more bacterial strains are selectively engineered by the same bacteriophage.

### Claim 6

The method of any of the preceding claims wherein the subject is a mammal.

### Claim 7 (depends on 4)

The method of claim 4 wherein the mammal is a human.

### Claim 8

The method of any of the preceding claims wherein the at least one bacteriophage is selected from the group consisting of M13, T7, T4, lambda, T3, T1, P1 and Mu, and derivatives thereof.

### Claim 9 (depends on 8)

The method of claim 8 wherein 1, 2, 3, 4, 5 or more bacteriophage are administered.

### Claim 10

The method of any of the preceding claims wherein the nucleic acid is a phagemid, a cosmid, and a phage-plasmid hybrid vector suitable for use with said at least one bacteriophage.

### Claim 11 (depends on 10)

The method of claim 10 wherein the nucleic acid comprises a phage-plasmid hybrid vector.

### Claim 12 (depends on 11)

The method of claim 11 wherein the phage-plasmid hybrid vector comprises one or more genes encoding a protein, an enzyme, or an RNA.

### Claim 13 (depends on 12)

The method of claim 12 wherein the one or more genes is an antibiotic resistance gene.

### Claim 14 (depends on 12)

The method of claim 12 wherein the one or more genes encode an RNA-guided nuclease.

### Claim 15 (depends on 14)

The method of claim 14 wherein the RNA-guided nuclease is Cas9.

### Claim 16 (depends on 15)

The method of claim 15 wherein the Cas9 specifically targets an antibiotic resistance gene in the at least one bacterial species.

### Claim 17 (depends on 10)

The method of claim 10 wherein the one or more genes encodes an enzyme selected from the group consisting of: an enzyme for drug activation, an enzyme for drug detoxification, an enzyme for transformation of dietary components into beneficial compounds for the host, an enzyme involved in one or more biosynthetic pathways for de novo production of beneficial compounds for the host (e.g. anti-inflammatory), an enzyme to aid long-term engraftment of the strain in the host gut, and an enzyme to increase competitive advantage of the strain in the host gut relative to the parent strain before gene delivery.

### Claim 18

A method of treating a disease associated with at least one bacterial strain among a mixed population of bacterial strains in the gut of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes.

### Claim 19

A method of increasing the growth of one or more target strain or species or genus in the gut microbiota of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes.

### Claim 20

A method of eliminating or reducing the population of one or more target strain or species or genus from an established community in the gut microbiota of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain or species or genus under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes.

### Claim 21

A method of conferring antibiotic resistance to one or more strain or species or genus of bacteria in an established community in the gut microbiota of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain or species or genus under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes that confer antibiotic resistance.

### Claim 22

A method of modifying the genome of one or more strain or species or genus of bacteria in an established community in the gut microbiota of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain or species or genus under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes.

### Claim 23

A method of upregulating or downregulating at least one gene in one or more strain or species or genus of bacteria in an established community in the gut microbiota of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain or species or genus under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes or encodes for a functional RNA molecule capable of upregulating or downregulating the at least one gene.

### Claim 24

A method of selectively removing at least one bacterial strain or species or genus from a population of bacteria in the gut of a subject comprising administering at least one bacteriophage to said subject comprising at least one nucleic acid, wherein said bacteriophage selectively infects the at least one bacterial strain or species or genus under conditions that allow expression of said at least one nucleic acid, wherein said at least one nucleic acid comprises one or more genes.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12)

The method of any one of claims 1-7, 9-12, and 18-24, wherein the bacteriophage is selected from the group consisting of M13, T7, T4, lambda, T3, T1, P1 and Mu, and derivatives thereof, and wherein said at least one nucleic acid encodes one or more sequences or genes involved in RNA-guided genome modification.

### Claim 26 (depends on 25)

The method of claim 25, wherein the bacteriophage is M13 and wherein said M13 comprises a nucleotide sequence encoding Cas9.
